文献速递类风湿关节炎

早期类风湿关节炎达标治疗策略与常规诊疗的比较性临床实践研究

Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study.
PubMed 文献 · Semin Arthritis Rheum · 2018-07-25

该研究比较了挪威早期关节炎队列2.0中按达标治疗(T2T)原则管理的293例早期类风湿关节炎(RA)患者与常规诊疗队列392例患者,主要结局为2年时SDAI缓解(≤3.3)。T2T队列2年SDAI缓解率为46%,常规诊疗队列为31%;2年时EQ-5D在两组间差异显著,甲氨蝶呤单药是两队列达到SDAI缓解的主要改善病情抗风湿药方案。

要点

  • T2T队列2年SDAI缓解率为46%,常规诊疗队列为31%。
  • 2年时EQ-5D中位数T2T队列0.77 vs 常规诊疗队列0.73,p < 0.001。
  • 甲氨蝶呤单药是两队列达到SDAI缓解的主要改善病情抗风湿药方案。

核心结论

  • 在临床实践中遵循T2T策略的患者比常规诊疗患者获得更高的缓解率和更好的健康相关生活质量。

研究设计与样本

  • 比较性临床实践研究,T2T队列为挪威早期关节炎队列2.0(NOR-VEAC 2.0)中2010—2015年纳入、按T2T原则治疗的患者293例,常规诊疗队列为挪威改善病情抗风湿药登记(NOR-DMARD)中2006—2009年纳入的T2T前患者392例。
  • 两组均为临床诊断RA(≤1年)且未使用过改善病情抗风湿药。
  • T2T队列访视时间为基线、3、6、9、12个月,之后每6个月访视一次,并每月访视直至DAS28 <2.6。
  • 主要结局为2年时SDAI缓解(≤3.3)。

主要发现

  • T2T队列293例,平均(SD)年龄54(13)岁,女性66%,病程中位数(25,75百分位)98(57,164)天。
  • 常规诊疗队列392例,平均(SD)年龄54(13)岁,女性68%,自诊断起中位数(25,75百分位)4(0,30)天。
  • 2年时达到SDAI缓解的比例T2T队列为46%,常规诊疗队列为31%。
  • EQ-5D基线时两组相似,2年时两组差异显著:中位数(25,75百分位)T2T队列0.77(0.69,0.85)vs 常规诊疗队列0.73(0.59,0.80),p < 0.001。
  • 甲氨蝶呤单药是两队列达到SDAI缓解的主要改善病情抗风湿药方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the 2-year effect on disease activity and health-related quality of life (HRQoL) of implementing a clinical practice treat-to-target (T2T) strategy in patients with rheumatoid arthritis (RA). METHODS: Patients in the Norwegian Very Early Arthritis Cohort 2.0 (NOR-VEAC 2.0), included 2010-2015, were treated according to T2T principles with visits at baseline, 3, 6, 9, 12 months, then every 6 months plus monthly visits until DAS28 <2.6. These patients were compared to a pre-T2T cohort of patients included in the Norwegian Disease Modifying Anti-Rheumatic Drug (NOR-DMARD) register 2006-2009. Both groups had a clinical diagnosis of RA (≤1 year) and were DMARD naïve. Disease activity and HRQoL outcomes were analysed, and the primary outcome was SDAI remission (≤3.3) at 2years. RESULTS: The T2T cohort included 293 patients (mean (SD) age 54 (13) years, 66% females, disease duration median (25,75 perc) 98 (57,164) days) and the routine care cohort 392 patients (age 54 (13) years, 68% females, 4 (0,30) days since diagnosis). At 2years, the proportion of patients achieving SDAI remission was 46% in the T2T cohort compared to 31% in the routine care cohort. EQ-5D was similar at baseline, but differed significantly between groups at 2years (median (25,75 perc) 0.77 (0.69, 0.85) vs 0.73 (0.59, 0.80), p < 0.001). Methotrexate monotherapy was the dominant DMARD regimen used to achieve SDAI remission in both cohorts. CONCLUSION: Higher remission rates and better HRQoL were achieved in patients following a T2T strategy in clinical practice compared to routine care.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Brinkmann GH, Norvang V, Norli ES, et al. Treat to target strategy in early rheumatoid arthritis versus routine care - A comparative clinical practice study. Semin Arthritis Rheum. 2018. PMID: 30205983. doi:10.1016/j.semarthrit.2018.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。